UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of January 2026
Commission
File Number: 001-40678
EUDA
Health Holdings Limited
(Exact
Name of Registrant as Specified in its Charter)
60
Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: +65 6327 1110
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form
40-F ☐
On
January 7, 2026, EUDA Health Holdings Limited issued the press release attached herewith as Exhibit 99.1.
Exhibits
| 99.1 |
Press release dated January 7, 2026. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
| Dated:
January 7, 2026 |
|
| |
|
| EUDA
Health Holdings Limited |
|
| |
|
| By: |
/s/
Alfred Lim |
|
| |
Alfred
Lim |
|
| |
Chief
Executive Officer |
|
Exhibit
99.1
EUDA
Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement
SINGAPORE,
Jan. 07, 2026 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a
Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has entered
into an amendment (the “Warrant Amendment”) to its previously disclosed warrant agreement with Streeterville Capital, LLC
(“Streeterville Capital”).
Background
on the Original Warrant Transaction
As
previously announced, on November 26, 2025, EUDA entered into a securities purchase agreement with Streeterville Capital, a Utah limited
liability company, for the issuance of a warrant (the “Warrant”) exercisable into up to 2,000,000 newly issued ordinary shares
of EUDA for an aggregate purchase price of US$100,000. The Warrant was issued on December 4, 2025. The offer and sale of the Warrant
and the Warrant Shares were made pursuant to a prospectus supplement dated December 4, 2025, as part of a registration statement on Form
F-3 (File No. 333-282723), which was filed with the Securities and Exchange Commission on October 18, 2024 and declared effective on
November 4, 2024. The Warrant may be exercised for cash for ninety (90) days (unless extended by the parties) from the date of issuance
(the “Cash Exercise Period”). At the end of two weeks after the Cash Exercise Period has expired, Streeterville Capital will
automatically be deemed to have made a “cashless” exercise of the Warrant, and the Company will be required to issue to Streeterville
Capital one (1) ordinary share for every ten (10) outstanding Warrant Shares for no additional consideration.
Summary
of Amended Terms
On
December 16, 2025, EUDA and Streeterville Capital entered into the Warrant Amendment to (i) reduce the exercise price of the Warrant
from US$6.00 per share to US$4.00 per share and (ii) reduce the minimum closing price required to trigger a “Forced Exercise”
(defined in the Warrant) from US$7.50 to US$6.00. All other terms of the warrant remain unchanged.
About
EUDA Health Holdings Limited
EUDA
Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore,
Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the
fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which
is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and
science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment
to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
Forward-Looking
Statements
This
document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words,
such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,”
“forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,”
“will,” “should,” “future,” “propose” and variations of these words or similar expressions
(or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions
or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are
outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking
statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document.
The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
